A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Schizophrenia
- Focus Pharmacodynamics
- Sponsors Alkermes
- 18 Aug 2017 Status changed from recruiting to completed.
- 28 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2017.
- 28 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.